Arena's obesity drug fails to impress in Phase III
This article was originally published in Scrip
Executive Summary
Despite announcing positive top-line data for its lead candidate, lorcaserin, from the first of two pivotal Phase III trials for obesity, Arena Pharmaceuticals' share price fell by 28% to close at $3.23 on Nasdaq as investors labelled the results disappointing.